BRD7116 |
| Catalog No.GC12811 |
BRD7116 se lie de manière compétitive À l'ADN gyrase bactérienne, présente une CE50 de 200 nM pour les cellules LSCe, avec une activité anti-leucémique non autonome des cellules.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 329059-55-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BRD7116, a bis-aryl sufone, acts as a selective inhibitor of leukemia stem cell activity by directly acting on the stromal cells to inhibit cobblestone formation [1,2].
BRD7116 displayed cell-non-autonomous anti-leukemia activity. In leukemia stem cells isolated from the bone marrow of leukemic animals in co-culture, BRD7116 exhibited an EC50 of 200 nM. BRD7116 displayed limited activity against normal HSPCs and AML cell lines with EC50s about 20 μM. BRD7116 showed activity against patient-derived primary human leukemia cells. Treatment of LSCe cells with BRD7116 induced transcriptional changes. The mechanism by which BRD7116 impaired the stroma’s ability to support leukemia cells has remained an important issue for future determination [1].
References:
[1] Hartwell K A, Miller P G, Mukherjee S, et al. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells[J]. Nature chemical biology, 2013, 9(12): 840-848.
[2] Sachlos E, Kerstetter-Fogle A. Research Highlights: Highlights from the latest articles in regenerative medicine[J]. Regenerative medicine, 2014, 9(2): 145-147.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *